Time filter

Source Type

Castelló de la Plana, Spain

Legaz-Arrese A.,University of Zaragoza | Lopez-Laval I.,University of Zaragoza | George K.,Liverpool John Moores University | Puente-Lanzarote J.J.,University of Zaragoza | And 4 more authors.
Applied Physiology, Nutrition and Metabolism | Year: 2015

This study had two objectives: (i) to examine individual variation in the pattern of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) release in response to high-intensity rowing exercise, and (ii) to establish whether individual heterogeneity in biomarker appearance was influenced by athletic status (elite vs. amateur). We examined cTnI and NT-proBNP in 18 elite and 14 amateur rowers before and 5 min, 1, 3, 6, 12, and 24 h after a 30-min maximal rowing test. Compared with pre-exercise levels, peak postexercise cTnI (pre: 0.014 ± 0.030 μg·L-1; peak post: 0.058 ± 0.091 μg·L-1; p = 0.000) and NT-proBNP (pre: 15 ± 11 ng·L-1; peak post: 31 ± 19 ng·L-1; p = 0.000) were elevated. Substantial individual heterogeneity in peak and time-course data was noted for cTnI. Peak cTnI exceeded the upper reference limit (URL) in 9 elite and 3 amateur rowers. No rower exceeded the URL for NT-proBNP. Elite rowers had higher baseline (0.019 ± 0.038 vs. 0.008 ± 0.015 -1g·L-1; p = 0.003) and peak postexercise cTnI (0.080 ± 0.115 vs. 0.030 ± 0.029 -1g·L-1; p = 0.022) than amateur rowers, but the change with exercise was similar between groups. There were no significant differences in baseline and peak postexercise NT-proBNP between groups. In summary, marked individuality in the cTnI response to a short but high-intensity rowing bout was observed. Athletic status did not seem to affect the change in cardiac biomarkers in response to high-intensity exercise. © 2015, National Research Council of Canada. All rights reserved. Source

Gil M.J.,Institute Catala dOncologia IDIBELL | De Las Penas R.,Consorcio Hospitalario Provincial de Castellon | Reynes G.,Hospital Universitario La Fe Of Valencia | Balana C.,Institute Catala dOncologia | And 11 more authors.
Anti-Cancer Drugs | Year: 2012

There is no 'standard of care' for recurrent malignant glioma (MG). Our aim is to confirm the efficacy and safety of bevacizumab 10 mg/kg plus irinotecan 125 mg/m (or 340 mg/m if enzyme-inducing antiepileptic drugs) every 2 weeks for a maximum of 1 year in a retrospective pooled series of patients with recurrent MG. The inclusion criteria were as follows: age 18 years and above, histology of MG, progression after radiation and temozolomide, Karnofsky performance status (KPS) of at least 60, and signed informed consent for bevacizumab compassionate use. Response was assessed by MRI using the Macdonald criteria and evaluation of the FLAIR sequence every 8 weeks. A total of 130 patients were enrolled; 72% had glioblastoma (GBM). The median age of the patients was 53 years (20-78); the median KPS was 80%; the median number of prior chemotherapy lines was 2 (1-5); the median interval between the diagnosis of MG and inclusion was 14.6 months (2-166); and the median number of bevacizumab infusions was 8 (1-39). The median follow-up duration was 7.2 months (1-47). The median overall survival (OS) was 8.8 months for GBM and 11.2 months for anaplastic glioma (AG). The median progression-free survival was 5.1 months for GBM and 4.6 months for AG. The response rate was 56% for GBM and 68% for AG. Neurological and KPS improvements were observed in 49 and 45% of patients. Only KPS less than 80% was associated with a worse significant response rate (odds ratio, 0.57; 95% confidence interval, 0.22-0.96). The most frequent grades 3-4 toxicities were asthenia (7%), diarrhea (6%), and thromboembolic events (5%). There were five toxic deaths (4%). Bevacizumab plus irinotecan in recurrent MG improves responses, progression-free survival, and OS compared with historical data. KPS of at least 80% was a predictive factor for response and OS. © 2012 Wolters Kluwer Health | Lippincott Williams &Wilkins. Source

Herraiz Roda J.L.,General University Hospital of Castellon | Llueca Abella J.A.,General University Hospital of Castellon | Maazouzi Y.,General University Hospital of Castellon | Bouche Babiloni A.,Consorcio Hospitalario Provincial de Castellon | And 3 more authors.
Gynecological Surgery | Year: 2016

The purposes of this study are to demonstrate our experience in using the “lotus petal” suprafascial flap and to evaluate the postoperative complications. During the period ranging from July 2012 to March 2015, nine patients diagnosed with primary or recurrent vulvar cancer have undergone radical vulvectomy followed by reconstructive surgery. Seventeen lotus petal suprafascial flap surgeries were performed. The average age of the patients was 79 years. No intraoperative complications were reported. The surgery length was 180 min with an estimated blood loss of 400 cc. Severe postoperative complications were rare. There were no complications associated with the donor site, nor were there any losses due to total or partial flap tissue necrosis. There were 2 (22.2 %) cases of partial wound dehiscence, which did not require re-intervention. The lotus petal suprafascial flap is a simple procedure that can be done during the same surgery as the radical vulvectomy, improving the aesthetic results and reducing both the rate of complications and hospital stay. © 2015, Springer-Verlag Berlin Heidelberg. Source

De las Penas R.,Consorcio Hospitalario Provincial de Castellon | Escobar Y.,Hospital General Universitario Gregorio Maranon | Henao F.,Hospital Universitario Virgen Of La Macarena | Blasco A.,Hospital General Universitario Of Valencia | Rodriguez C.A.,Hospital Universitario Of Salamanca Ibsal
Clinical and Translational Oncology | Year: 2014

Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneoplastic syndrome, we must not forget that very often, these disorders could be caused by various drugs, including some of the antineoplastic agents most frequently used, such as platin derivatives or some biologics. These guidelines review major management of diagnosis, evaluation and treatment of the most common alterations of sodium, calcium, magnesium and potassium in cancer patients. Aside from life-sustaining treatments, we have reviewed the role of specific drug treatments aimed at correcting some of these disorders, such as intravenous bisphosphonates for hypercalcemia or V2 receptor antagonists in the management of syndrome of inappropriate antidiuretic hormone secretion-related hyponatremia. © 2014, The Author(s). Source

De las Penas R.,Consorcio Hospitalario Provincial de Castellon | Ponce S.,Hospital 12 de Octubre | Henao F.,Hospital Universitario Virgen Of La Macarena | Camps Herrero C.,University of Valencia | And 5 more authors.
Supportive Care in Cancer | Year: 2016

Hyponatremia (Na ˂135 mmol/l) is the most frequent electrolyte disorder in clinical practice, and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the commonest cause of hyponatremia in cancer patients. Correcting hyponatremia in these patients can reduce morbidity and mortality, increase the response to anti-cancer agents, and help reduce hospital length of stay and costs. Tolvaptan is an oral medication used to treat SIADH-related hyponatremia patients that needs to be initiated at hospital so patients can have their serum sodium monitored. If tolvaptan could be initiated in hospital day care units (DCUs), performing the same tests, hospitalization could be avoided, quality of life improved, and costs reduced. This is the first publication where a panel of oncologists are sharing their experience and making some recommendations with the use of tolvaptan to treat SIADH-related hyponatremia in DCU after collecting and examining 35 clinical cases with these type of patients. The conclusion from this retrospective observational analysis is that the use of tolvaptan in DCU is safe and effective in the therapeutic management of SIADH-related hyponatremia. © 2015, The Author(s). Source

Discover hidden collaborations